These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24013904)

  • 1. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
    Lee SJ; Lee J; Lee J; Park SH; Park JO; Park YS; Lim HY; Kim KM; Do IG; Jung SH; Yim DS; Kang WK
    Invest New Drugs; 2013 Dec; 31(6):1580-6. PubMed ID: 24013904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
    Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
    Kordes S; Richel DJ; Klümpen HJ; Weterman MJ; Stevens AJ; Wilmink JW
    Invest New Drugs; 2013 Feb; 31(1):85-91. PubMed ID: 22367239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
    Shin SJ; Jeung HC; Ahn JB; Choi HJ; Cho BC; Rha SY; Yoo NC; Roh JK; Chung HC
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):157-65. PubMed ID: 17426971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Kim TW; Kang YK; Ahn JH; Chang HM; Yook JH; Oh ST; Kim BS; Lee JS
    Ann Oncol; 2002 Dec; 13(12):1893-8. PubMed ID: 12453857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
    Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Liu C; Sun Q; Hang X; Zhong B; Wang D
    Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
    Liu Y; Ma T; Ye ZB; Zhang J; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Mar; 13(3):177-80. PubMed ID: 20336533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
    Luo HY; Wang ZQ; Wang FH; Qiu MZ; Teng KY; Ruan DY; He YJ; Li YH; Xu RH
    Am J Clin Oncol; 2011 Dec; 34(6):555-60. PubMed ID: 22101386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.